TYRP1-directed CAR T-cell therapy demonstrates efficacy in preclinical melanoma models
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma. CAR T-cell therapy uses genetically engineered versions of a patient’s immune cells to target and destroy cancer cells. … Read more